doi:10.3969/j.issn.1004-583X.2022.10.013

Abstract

CLC Number:

R541.75

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.10.013

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I10/946

References 27

[1]	Carlisle MA, Fudim M, DeVore AD, et al. Heart failure and atrial fibrillation,like fire and fury[J]. JACC Heart Fail, 2019, 7(6):447-456. doi: 10.1016/j.jchf.2019.03.005 URL
[2]	Zimetbaum P. Atrial fibrillation[J]. Ann Intern Med, 2017, 166(5):ITC33-ITC48. doi: 10.7326/AITC201703070 URL
[3]	Qiu D, Peng L, Ghista DN, et al. Left atrial remodeling mechanisms associated with atrial fibrillation[J]. Cardiovasc Eng Technol, 2021, 12(3):361-372. doi: 10.1007/s13239-021-00527-w pmid: 33650086
[4]	Dridi H, Kushnir A, Zalk R, et al. Intracellular calcium leak in heart failure and atrial fibrillation: A unifying mechanism and therapeutic target[J]. Nat Rev Cardiol, 2020, 17(11):732-747. doi: 10.1038/s41569-020-0394-8 URL
[5]	Beyer C, Tokarska L, Stühlinger M, et al. Structural cardiac remodeling in atrial fibrillation[J]. JACC Cardiovasc Imaging, 2021, 14(11):2199-2208. doi: 10.1016/j.jcmg.2021.04.027 URL
[6]	Yamaguchi N, Xiao J, Narke D, et al. Cardiac pressure overload decreases ETV1 expression in the left atrium, contributing to atrial electrical and structural remodeling[J]. Circulation, 2021, 143(8):805-820. doi: 10.1161/CIRCULATIONAHA.120.048121 pmid: 33225722
[7]	Menanga AP, Nganou-Gnindjio CN, Ahinaga AJ, et al. Left atrial structural and functional remodeling study in type 2 diabetic patients in sub-Saharan Africa: Role of left atrial strain by 2D speckle tracking echocardiography[J]. Echocardiography, 2021, 38(1):25-30. doi: 10.1111/echo.14915 pmid: 33124110
[8]	Sheng X, Scherlag BJ, Yu L, et al. Prevention and reversal of atrial fibrillation inducibility and autonomic remodeling by low-level vagosympathetic nerve stimulation[J]. J Am Coll Cardiol, 2011, 57(5):563-571. doi: 10.1016/j.jacc.2010.09.034 pmid: 21272747
[9]	Oliveira ÍM, Silva Júnior ELD, Martins YO, et al. Cardiac autonomic nervous system remodeling may play a role in atrial fibrillation: A study of the autonomic nervous system and myocardial receptors[J]. Arq Bras Cardiol, 2021, 117(5):999-1007. doi: 10.36660/abc.20200725 pmid: 34406322
[10]	Qin M, Zeng C, Liu X. The cardiac autonomic nervous system: A target for modulation of atrial fibrillation[J]. Clin Cardiol, 2019, 42(6):644-652. doi: 10.1002/clc.23190 pmid: 31038759
[11]	Ono K. How is uric acid related to atrial fibrillation?[J]. Circ J, 2019, 83(4):705-706. doi: 10.1253/circj.CJ-19-0134 pmid: 30814432
[12]	Taufiq F, Li P, Miake J. Hyperuricemia as a risk factor for atrial fibrillation due to soluble and crystalized uric acid[J]. Circ Rep, 2019, 1(11):469-473. doi: 10.1253/circrep.CR-19-0088 pmid: 33693087
[13]	Yao Y, Shang MS, Dong JZ. Homocysteine in non-valvular atrial fibrillation: Role and clinical implications[J]. Clin Chim Acta, 2017, 475:85-90. doi: S0009-8981(17)30408-4 pmid: 29050786
[14]	Dong XJ, Wang BB, Hou FF, et al. Homocysteine (HCY) levels in patients with atrial fibrillation (AF): A meta-analysis[J]. Int J Clin Pract, 2021, 75(12):e14738.
[15]	Steed MM, Tyagi SC. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia[J]. Antioxid Redox Signal, 2011, 15(7):1927-1943. doi: 10.1089/ars.2010.3721 URL
[16]	Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation[J]. Circulation, 2004, 109(3):363-368. pmid: 14732752
[17]	Canpolat U, Oto A, Hazirolan T, et al. A prospective DE-MRI study evaluating the role of TGF-β1 in left atrial fibrosis and implications for outcomes of cryoballoon-based catheter ablation: New insights into primary fibrotic atriocardiomyopathy[J]. J Cardiovasc Electrophysiol, 2015, 26(3):251-259.
[18]	Cai B, Shan L, Gong D, et al. Homocysteine modulates sodium channel currents in human atrial myocytes[J]. Toxicology, 2009, 256(3):201-206. doi: 10.1016/j.tox.2008.11.020 pmid: 19110030
[19]	Cai BZ, Gong DM, Liu Y, et al. Homocysteine inhibits potassium channels in human atrial myocytes[J]. Clin Exp Pharmacol Physiol, 2007, 34(9):851-855. doi: 10.1111/j.1440-1681.2007.04671.x URL
[20]	Law P, Kharche S, Stott J, et al. Effects of elevated Homocysteine hormone on electrical activity in the human atrium: A simulation study[J]. Annu Int Conf IEEE Eng Med Biol Soc, 2009, 2009:3936-3939. doi: 10.1109/IEMBS.2009.5333530 pmid: 19964086
[21]	Mishra PK, Tyagi N, Kundu S, et al. MicroRNAs are involved in homocysteine-induced cardiac remodeling[J]. Cell Biochem Biophys, 2009, 55(3):153-162. doi: 10.1007/s12013-009-9063-6 pmid: 19669742
[22]	Si Y, Fan W, Sun L. A review of the relationship between CTRP family and coronary artery disease[J]. Curr Atheroscler Rep, 2020, 22(6):22. doi: 10.1007/s11883-020-00840-0 pmid: 32468164
[23]	Li Y, Wright GL, Peterson JM. C1q/TNF-related protein 3 (CTRP3) function and regulation[J]. Compr Physiol, 2017, 7(3):863-878. doi: 10.1002/cphy.c160044 pmid: 28640446
[24]	Mourilhe-Rocha R, Bittencourt MI. CTRP-3 levels in patients with stable coronary artery disease and paroxysmal atrial fibrillation: A new potential biomarker in cardiovascular diseases[J]. Arq Bras Cardiol, 2022, 118(1):59-60. doi: 10.36660/abc.20210940 pmid: 35195209
[25]	Sonmez O, Ertem FU, Vatankulu MA, et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation[J] .Med Sci Monit, 2014, 20: 463-470. doi: 10.12659/MSM.890635 URL
[26]	Scaglione M, Gallo C, Battaglia A, et al. Long-term progression from paroxysmal to permanent atrial fibrillation following transcatheter ablation in a large single-center experience[J]. Heart Rhythm, 2014, 11: 777-782. doi: 10.1016/j.hrthm.2014.02.018 pmid: 24561164
[27]	Ko D, Benson MD, Ngo D, et al. Proteomics profiling and risk of new-onset atrial fibrillation: Framingham heart study[J]. J Am Heart Assoc, 2019, 8(6):e010976. doi: 10.1161/JAHA.118.010976 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 27

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Yihan, Qin Xuyan, Han Xuanze, Wang Yingjie, Gao Feifei, Chen Chunhong, Zhang Lingnan, Zhang Fang. Efficacy and safety of rivaroxaban therapy in elderly patients with non-valvular atrial fibrillation who had a HASBLED score≥3 [J]. Clinical Focus, 2024, 39(2): 121-124.
[2]	. [J]. Clinical Focus, 2024, 39(2): 168-171.
[3]	Zhang Fang, Zhang Yichao, Jia Xinwei, Li Jianlong, Chen Chunhong. Analysis of one-year follow-up results of ≥75-year-old atrial fibrillation inpatients with high CHA2DS2-VASc score [J]. Clinical Focus, 2023, 38(2): 117-120.
[4]	Li Weiwei, Li Yanan. Left atrial volume index predicts atrial fibrillation recurrence after radiofrequency ablation: A meta-analysis [J]. Clinical Focus, 2022, 37(11): 965-968.
[5]	Zhang Haifu, Ye Xiangqing, Chen Zhexu, Chen Shijian, Yang Dong, Zhang Xingwei. Effects of moderate exercise on the prognosis of patients with atrial fibrillation:A systematic review and Meta-analysis [J]. Clinical Focus, 2022, 37(6): 485-489.
[6]	Zhao Meili, Xiao Liyuan, Liu Lin, Kang Chao, Zhang Qiuxiang. Correlation between NT-proBNP, hs-CRP, left atrium diameter and chronic heart failure concurrent with atrial fibrillation [J]. Clinical Focus, 2021, 36(5): 412-415.
[7]	Lu Yuqin, Li Yingdong, Liu Kai. Role of serum MMP-1, MMP-3, TIMP-1 and Hcy levels in patients with hypertension complicated with atrial fibrillation [J]. Clinical Focus, 2020, 35(11): 976-979.
[8]	Guo Xueyuan, Ma Changsheng. Atrial fibrillation treatment: present state and future directions [J]. Clinical Focus, 2016, 31(1): 7-9.
[9]	Qi Shuyuan,Tian Ying. Role of percutaneous left atrial appendage occlusion in stroke prevention for nonvalvular atrial fibrillation [J]. Clinical Focus, 2016, 31(1): 10-13.
[10]	Xue Li, Cai Heng. Anticoagulation advance in atrial fibrillation [J]. Clinical Focus, 2016, 31(1): 14-18.
[11]	Xie Ruiqin, Yin Guangli, Yang Yingtao. The status and advances of radiofrequency catheter ablation for atrial fibrillation [J]. Clinical Focus, 2016, 31(1): 19-21.
[12]	Liu Hongbin, Wang Xiaoyan, Zhang Zhigang, Ji Zhenguo. Treatment of acute atrial fibrillation [J]. Clinical Focus, 2016, 31(1): 22-26.
[13]	Qi Shuying, Yuan Xiaohong. Drug therapy of atrial fibrillation with organic heart disease [J]. Clinical Focus, 2016, 31(1): 27-29.
[14]	Ding Chao. Progress of treatment strategy in atrial fibrillation with non-structural heart disease [J]. Clinical Focus, 2016, 31(1): 30-33.
[15]	. [J]. Clinical Focus, 2015, 30(11): 1316-1320.